Screener
Corvus Pharmaceuticals CRVS Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Corvus Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-057100
FAQ
- What is Corvus Pharmaceuticals's debt-to-equity?
- Corvus Pharmaceuticals (CRVS) reported debt-to-equity of 0× in Q1 2026.
- How has Corvus Pharmaceuticals's debt-to-equity changed year-over-year?
- Corvus Pharmaceuticals's debt-to-equity decreased by 85.0% year-over-year, from 0× to 0×.
- What is the long-term trend for Corvus Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Corvus Pharmaceuticals's debt-to-equity has grown at a -13.7% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Corvus Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude